NANOCARRIER BASED INTRALYMPHATIC IMAGING AND THERAPY FOR MELANOMA

基于纳米载体的淋巴内成像和黑色素瘤治疗

• 批准号: 7959404
• 负责人: Mark Steven Cohen
• 金额: $ 14.1万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7959404
• 关键词: Cancer Center; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Cutaneous Melanoma; Disease; Drops; Drug Delivery Systems; Funding; Gadolinium; Goals; Grant; Hyaluronic Acid; Image; Institution; Lymphatic; Magnetic Resonance Imaging; Melphalan; Methods; Modality; Morbidity - disease rate; Nanotechnology; Neoplasm Metastasis; Organ; Pharmaceutical Preparations; Research; Research Personnel; Resources; Site; Skin; Skin Cancer; Source; Staging; Survival Rate; System; Therapeutic; Toxic effect; United States National Institutes of Health; base; cancer imaging; falls; improved; lymph nodes; melanoma; nanocarrier; novel; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The rate of melanoma skin cancer is increasing yearly with 60000 new cases in 2007 in the US alone. Melanoma is highly curable if treated before it has spread from the primary site on the skin, but 5-year survival rates drop to only 29% once disease has spread to lymph nodes and fall even lower (down to 7%) if tumors metastasize to major organs. The goal of this proposal is to devetop and optimize a new drug-delivery and imaging platform for melanoma staging and treatment. Since melanomas naturally spread initially through local lymphatic channels and lymph nodes, this delivery and imaging system will specifically target the lymphatics. Using nanotechnology, hyaluronic acid, a compound naturally found in the body, is combined with drugs like melphalan normally used in regional therapy for melanoma, and delivered through the lymphatics. By lymphatic drug-delivery, the tumor is treated in a targeted manner, decreasing the amount of drug absorbed systemically which should result in a lower toxicity profile than the way it is currently administered. In addition to treating early melanoma through the lymphatics, this nanocarrier can be combined with gadolinium and imaged by MRI. Utilizing intralyrnphatic delivery for a contrast agent, this proposal will also explore novel ways to image lymphatically spread tumors such as melanoma. If successful, this research will result in an improved method for treating and imaging early to intermediate stage melanoma avoiding the morbidity of current treatment modalities and advancing the field of cancer imaging and therapeutics for lymphatically spread tumors.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 黑色素瘤皮肤癌的发病率每年都在增加，仅在美国2007年就有60000例新发病例。如果在黑色素瘤从皮肤原发部位扩散之前进行治疗，黑色素瘤是高度可治愈的，但是一旦疾病扩散，5年生存率下降到只有29%。 扩散到淋巴结，如果肿瘤转移到主要器官，则下降甚至更低（下降至7%）。该提案的目标是开发和优化一种新的药物输送和成像平台，用于黑色素瘤分期和治疗。因为黑色素瘤 最初通过局部淋巴通道和淋巴结扩散，这种递送和成像系统将特异性地靶向淋巴系统。利用纳米技术，透明质酸，一种在体内自然发现的化合物，与美法仑等药物结合 通常用于黑色素瘤的局部治疗，并通过血管内给药。 通过淋巴药物递送，肿瘤以靶向方式治疗，减少全身吸收的药物量，这应导致比目前施用方式更低的毒性特征。除了通过药物治疗早期黑色素瘤外，这种纳米载体还可以与钆结合并通过MRI成像。利用造影剂的淋巴内递送，该提议还将探索对诸如黑色素瘤的扩散性肿瘤进行成像的新方法。如果成功，这项研究将导致一种改进的方法，用于治疗和成像早期至中期黑色素瘤，避免目前治疗方式的发病率，并推进癌症成像和治疗恶性扩散肿瘤的领域。